Postoperative pulmonary complications in severe acute respiratory syndrome coronavirus 2 infected patients who underwent emergency surgery.
30-day mortality
coronavirus disease 2019
emergency surgery
postoperative pulmonary complications
severe acute respiratory syndrome coronavirus 2
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
revised:
11
06
2023
received:
17
05
2023
accepted:
12
06
2023
medline:
15
8
2023
pubmed:
6
7
2023
entrez:
5
7
2023
Statut:
ppublish
Résumé
Recent studies suggest that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection increases the incidence of postoperative pulmonary complications (PPCs) and mortality. Consequently, patients with SARS-CoV-2 infection undergoing emergency surgery are more vulnerable to PPCs, yet few studies have evaluated PPCs in these patients. A retrospective analysis was conducted between January 2022 and February 2023 on the medical records of patients infected with SARS-CoV-2 who underwent emergency surgery. The study evaluated the incidence of PPCs and 30-day postoperative mortality in all enrolled patients. A total of 41 patients were enrolled, among whom PPCs occurred in seven patients (17%). The incidence of PPCs was statistically significant in patients with underlying diabetes compared to those without (p = 0.01) and in patients with an American Society of Anesthesiologists (ASA) class 3 or higher compared to those with less than 3 (p = 0.005) (ASA classification uses a grading system of I (one) through V (five)). The 30-day mortality rate was 4.9%. Our study demonstrates that the incidence of PPCs and 30-day mortality rates after emergency surgery in patients infected with SARS-CoV-2 are higher compared to prepandemic baseline rates. Given the significant interest and concern worldwide regarding severe infectious respiratory diseases, such as coronavirus disease 2019 (COVID-19), clinicians should focus on conducting research to identify ways to reduce the incidence of PPCs and mortality in patients with severe acute respiratory infections.
Sections du résumé
BACKGROUND
Recent studies suggest that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection increases the incidence of postoperative pulmonary complications (PPCs) and mortality. Consequently, patients with SARS-CoV-2 infection undergoing emergency surgery are more vulnerable to PPCs, yet few studies have evaluated PPCs in these patients.
METHODS
A retrospective analysis was conducted between January 2022 and February 2023 on the medical records of patients infected with SARS-CoV-2 who underwent emergency surgery. The study evaluated the incidence of PPCs and 30-day postoperative mortality in all enrolled patients.
RESULTS
A total of 41 patients were enrolled, among whom PPCs occurred in seven patients (17%). The incidence of PPCs was statistically significant in patients with underlying diabetes compared to those without (p = 0.01) and in patients with an American Society of Anesthesiologists (ASA) class 3 or higher compared to those with less than 3 (p = 0.005) (ASA classification uses a grading system of I (one) through V (five)). The 30-day mortality rate was 4.9%.
CONCLUSIONS
Our study demonstrates that the incidence of PPCs and 30-day mortality rates after emergency surgery in patients infected with SARS-CoV-2 are higher compared to prepandemic baseline rates. Given the significant interest and concern worldwide regarding severe infectious respiratory diseases, such as coronavirus disease 2019 (COVID-19), clinicians should focus on conducting research to identify ways to reduce the incidence of PPCs and mortality in patients with severe acute respiratory infections.
Identifiants
pubmed: 37407283
doi: 10.1111/1759-7714.15016
pmc: PMC10423653
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2297-2301Informations de copyright
© 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
Br J Anaesth. 2017 Mar 1;118(3):317-334
pubmed: 28186222
Lancet. 2020 Jul 4;396(10243):27-38
pubmed: 32479829
BMC Surg. 2021 May 21;21(1):253
pubmed: 34020623
J Clin Anesth. 1995 Sep;7(6):491-9
pubmed: 8534467
Surgery. 2021 Feb;169(2):264-274
pubmed: 33158548
Curr Opin Anaesthesiol. 2007 Feb;20(1):37-42
pubmed: 17211165
ANZ J Surg. 2021 Jan;91(1-2):33-41
pubmed: 33369009
Ann Transl Med. 2018 Oct;6(19):379
pubmed: 30460253
Ann Surg. 2020 Aug;272(2):e79-e80
pubmed: 32675504
Thorac Cancer. 2023 Aug;14(23):2297-2301
pubmed: 37407283
Intern Emerg Med. 2020 Nov;15(8):1415-1424
pubmed: 32772283
Anaesthesia. 2021 Jun;76(6):748-758
pubmed: 33690889
Am J Respir Crit Care Med. 2005 Mar 1;171(5):514-7
pubmed: 15563632
Anesthesiology. 2010 Dec;113(6):1338-50
pubmed: 21045639
Int J Surg. 2015 Jun;18:184-90
pubmed: 25937154
Clin Podiatr Med Surg. 1990 Jul;7(3):467-81
pubmed: 2205347
Infect Control Hosp Epidemiol. 2014 Jun;35(6):660-6
pubmed: 24799642
Clin Immunol. 2020 Jun;215:108427
pubmed: 32325252
BMJ. 2020 Mar 11;368:m540
pubmed: 32161042
Korean J Anesthesiol. 2019 Feb;72(1):53-59
pubmed: 30424587
Best Pract Res Clin Anaesthesiol. 2010 Jun;24(2):157-69
pubmed: 20608554
Best Pract Res Clin Anaesthesiol. 2020 Jun;34(2):153-166
pubmed: 32711826
Semin Cardiothorac Vasc Anesth. 2020 Dec;24(4):293-303
pubmed: 32706293